135655-75-3

Upstream product

• 1571-08-0 methyl 4-formylbenzoate 
• 504-63-2 trimethyleneglycol 

Downstream Products

• 397328-79-9 4-(1,3-dioxan-2-yl)benzoic acid 
• 54274-80-5 trans-4-formyl-cyclohexanecarboxylic acid methyl ester 
• 1349171-54-5 methyl 4-formyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 

Relevant academic research and scientific papers

Nanostructured ruthenium on γ-Al2O3 catalysts for the efficient hydrogenation of aromatic compounds

Free and trioctylamine (TOA)-stabilized ruthenium nanoparticles have been prepared by decomposition of the metal precursor Ru(η6-cycloocta-1,3,5-triene) (η4-cycloocta-1,5-diene) under mild conditions (room temperature, hydrogen atmospheric pressure). The nanoparticles have been deposited on γ-Al2O3 supports having different surface area. The resulting systems are active in the hydrogenation of methyl benzoate to methyl cyclohexanoate with a reaction rate decreasing in the order Ru(TOA)/γ-Al2 O3 (high surface area, catalyst D)>Ru(TOA)/γ-Al2 O3 (catalyst C)>Ru/γ-Al2O3 (high surface area, catalyst B) > Ru/γ-Al2 O3 (catalyst A). Catalysts A-D are long lived and can be reused without loss of activity; they are considerably more active than a commercial ruthenium on γ-Al2O3 sample. High Resolution Transmission Electron Microscopy analyses of such systems show that the nanoparticles are homogeneously dispersed on the support and that the size distribution decreases in the order catalyst A, 2.9 nm > catalyst B, 2.8 nm>catalyst C, 2.4 nm > catalyst D, 2.3 nm. Based on the easy hydrogenation of the aromatic ring to the cyclohexane derivative, an efficient synthesis of 4-carbomethoxyformylcyclohexane, important starting material in the preparation of pharmaceutical products, from the largely available methyl 4-formylbenzoate, has been set up in the presence of catalyst D,

Discovery of novel multiacting topoisomerase I/II and histone deacetylase inhibitors

Designing multitarget drugs remains a significant challenge in current antitumor drug discovery. Because of the synergistic effect between topoisomerase and HDAC inhibitors, the present study reported the first-in-class triple inhibitors of topoisomerase I/II and HDAC. On the basis of 3-amino-10-hydroxylevodiamine and SAHA, a series of hybrid molecules was successfully designed and synthesized. In particular, compound 8c was proven to be a potent inhibitor of topoisomerase I/II and HDAC with good antiproliferative and apoptotic activities. This proof-of-concept study also validated the effectiveness of discovering triple topoisomerase I/II and HDAC inhibitors as novel antitumor agents.

Mesoporous poly-melamine-formaldehyde (mPMF)-a highly efficient catalyst for chemoselective acetalization of aldehydes

A mesoporous poly-melamine-formaldehyde polymer with a high surface area, good porosity and a high density of amine and triazine functional groups was investigated as a highly efficient hydrogen-bonding catalyst. This porous organic polymer was found to be highly effective in catalyzing chemoselective acetalization of aldehydes, without the consumption of any dehydrating agents. The turnover frequency of mesoporous poly-melamine-formaldehyde is hundreds of times higher than melamine monomer, and this high efficiency is due to the high density of aminal (-NH-CH2-NH-) groups and triazine rings in the polymer network, which provides an inherently powerful system with multiple hydrogen bonds. This unique characteristic imparts mesoporous poly-melamine-formaldehyde polymer with a very high activity as a heterogeneous organocatalyst. The polymer is also low cost, and easy to be synthesized and recycled.

A METHOD OF ACETALIZING AN ALDEHYDE

A method of acetalizing an aldehyde comprising reacting said aldehyde with an alcohol in the presence of a polymeric catalyst to form an acetal wherein the polymeric catalyst is a mesoporous poly-melamine-formaldehyde polymer.

FIBROSIS INHIBITOR

Medicament being useful as a fibrosis inhibitor for organs or tissues, which comprises a compound of the formula (I): wherein Ring Z is optionally substituted pyrrole ring, etc.; W2 is -CO-, -SO2-, optionally substituted C1-C4 alkylene, etc.; Ar2 is optionally substituted aryl, etc.; W1 and Ar1 mean the following (1) and (2):(1) W1 is optionally substituted C1-C4 alkylene, etc.; Ar1 is optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms:(2) W1 is optionally substituted C2-C5 alkylene, optionally substituted C2-C5 alkenylene, etc.; and Ar1 is aryl or monocyclic heteroaryl, which is substituted by carboxyl, alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof.

Pyrrole derivatives

Pyrrole derivatives represented by the following formula: wherein Ring Z is an optionally substituted pyrrole ring, etc.; W2 is —CO—, —SO2—, an optionally substituted C1-C4 alkylene, etc.; Ar2 is an optionally substituted aryl, etc.; W2 and Ar1 mean the following (1) and (2): (1) W1 is an optionally substituted C1-C4 alkylene, etc.; Ar1 is an optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms: (2) W1 is an optionally substituted C2-C5 alkylene, an optionally substituted C2-C5 alkenylene, etc.; and Ar1 is an aryl or monocyclic heteroaryl, which are substituted by carboxyl, an alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof These compounds are useful as medicaments such as a fibrosis inhibitor for organs or tissues.